Very positive handwriting on the wall, eerrr, chart.
NTII was scheduled to break the blind for the Neuropathic Pain Phase II clinical trial on the 8th of December. This means that who received Memantine and who received placebo is now known by the company and they are probably crunching the numbers even as you read this. They should have an announcement of the results before the end of the month. However, I'm sure the results for the primary endpoints have already been analyzed. In fact, they were probably analyzed within minutes of obtaining the list of Memantine and placebo patients. That means that NTII now knows whether Memantine worked or didn't.
The preliminary, group data, that were discussed at the annual stockholders meeting were suggestive of a very positive outcome. (see my post #718 this thread). Todays trading pattern with a sharp rise on heavy volume in the face of a NASDAQ selloff, I see as extremely bullish. NTII, like most small companies, has been leaky in the past. I can speculate that todays NTII rally could be an indication of positive results.
I can't overemphasize how important this would be for NTII. Neuropathic pain is a huge market and memantine will have to be taken on a chronic (continuous) basis by the sufferers and there is no alternative effective treatment available to relieve the suffering. NTII has, by agreement with Merz, the lions share of any profits or royalties earned on this indication. In other words, this is an immense potential profit machine for NTII. If the results are as positive as I anticipate, potential partners will line up to get in on this.
Best regards
John de C |
